Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
TipRanks (Mon, 13-Jul 4:58 PM ET)
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Globe Newswire (Mon, 13-Jul 4:05 PM ET)
Stifel Nicolaus Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks (Fri, 10-Jul 7:35 AM ET)
Globe Newswire (Tue, 7-Jul 8:00 AM ET)
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Globe Newswire (Fri, 19-Jun 4:02 PM ET)
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Globe Newswire (Thu, 28-May 8:00 AM ET)
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Globe Newswire (Tue, 12-May 5:00 PM ET)
Globe Newswire (Wed, 6-May 7:00 AM ET)
Globe Newswire (Tue, 5-May 7:00 AM ET)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Globe Newswire (Fri, 1-May 5:05 PM ET)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Eupraxia Pharmaceuticals trades on the NASDAQ stock market under the symbol EPRX.
As of July 15, 2026, EPRX stock price climbed to $6.52 with 132,167 million shares trading.
EPRX has a beta of 1.00, meaning it tends to be less sensitive to market movements. EPRX has a correlation of 0.08 to the broad based SPY ETF.
EPRX has a market cap of $425.93 million. This is considered a Small Cap stock.
EPRX has underperformed the market in the last year with a price return of +16.6% while the SPY ETF gained +22.0%. EPRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.7% and -1.4%, respectively, while the SPY returned +9.0% and +1.1%, respectively.
EPRX support price is $6.07 and resistance is $6.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EPRX shares will trade within this expected range on the day.
